Bedrijfsoverzicht
Annexon, Inc. is a clinical-stage biopharmaceutical entity dedicated to the discovery and development of therapeutic medicines designed to treat inflammatory-related diseases. The company operates within the broader Healthcare sector, specifically functioning in the Biotechnology industry, a segment characterized by high-risk research and development activities aimed at creating novel treatments. With a market capitalization of $938.77M and an employee base of 96, Annexon maintains a modest organizational scale relative to large-cap pharmaceutical peers, yet retains significant valuation weight. The market cap figure of $938.77M indicates that the market values the company's pipeline assets and future potential at a level substantially higher than its current operational revenue generation, reflecting the speculative nature typical of biotechnology firms in Phase 3 clinical trials. The annual revenue figure is not disclosed in the available data, but the valuation implies that the company's primary value driver is its investigational asset, Tanruprubart, rather than current sales performance.
Financiële gezondheid
The company reported a net income of $-208,547,008 and an EBITDA of $-214,240,992 over the trailing twelve months, while revenue data is not available in the provided metrics. The substantial negative gap between the unavailable revenue figure and the reported net loss reveals a cost structure dominated by heavy research and development expenditures typical of clinical-stage development, where expenses far exceed immediate income generation. Free cash flow stands at $-104,476,376, indicating that the company is consuming cash reserves to fund its operations and clinical trials, which limits immediate financial flexibility but is a standard requirement for advancing assets through late-stage development. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability or positive operational leverage from its sales activities. On the liability side, the company holds $238.34M in cash against $26.20M in debt, resulting in a debt-to-equity ratio of 12.38, suggesting a balance sheet that is leveraged in terms of equity ratios but heavily cash-rich in absolute terms. The current ratio is 5.68, indicating a very strong short-term liquidity position where current assets significantly exceed current liabilities, providing ample buffer against short-term obligations despite the negative earnings. Return on Equity is -81.9% and Return on Assets is -43.1%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic during the pre-commercialization phase of biotechnology companies.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -6.12, implying that the market expects earnings to remain negative or turn positive only in the distant future given the current financial trajectory. The price-to-book ratio is 4.13, which indicates a significant market premium over the company's book value, suggesting investors are pricing in substantial future value from the clinical pipeline that is not reflected on the balance sheet. The price-to-sales ratio is N/A because revenue data is unavailable, and the EV/EBITDA stands at -3.39, a metric that is negative and therefore not a standard comparable for valuation in the traditional sense for loss-making biotech firms. The stock has traded between a 52-week low of $1.40 and a 52-week high of $7.18, meaning the current price sits somewhere within this range, reflecting the high volatility inherent in clinical-stage assets. The beta value is 1.15, which indicates that the stock's price volatility is 15% higher than that of the broader market, exposing investors to increased systemic risk during periods of market turbulence.
Growth & Income
Revenue growth and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between the two metrics due to the lack of historical revenue data in the source material. As the company does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, meaning all available cash flow is reinvested into research, development, and clinical trial costs. The absence of a dividend yield confirms that the company follows a growth-oriented strategy where earnings are not distributed but rather retained to fund the expensive process of bringing medicines to market. Consequently, the overall growth and income profile is defined by total reliance on capital appreciation potential rather than income generation or dividend yields, positioning Annexon as a pure-play speculative investment dependent entirely on the successful progression of its clinical pipeline.